All the news Showing 10 of 448 articles from: TherapiesGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Australia: Treatment Has Changed campaign Hepatitis New South Wales / 17 February 2016 U.S. FDA Approves Two Supplemental Indications for Harvoni® in Chronic Hepatitis C Patients With Advanced Liver Disease Gilead press release / 17 February 2016 U.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C Bristol-Myers Squibb press release / 08 February 2016 Fair Pricing Coalition Recognizes Merck’s Lower Price for Curative Hepatitis C Treatment, Calls for Manufacturers to Reduce Excessive Prices and Increase Patient Assistance Fair Pricing Coalition / 08 February 2016 Olysio/Sovaldi yield high SVR post-liver transplant Healio / 08 February 2016 Merck Throws a Wrench in Drug Pricing Bloomberg / 01 February 2016 European Commission Approves Daklinza (daclatasvir) for the Treatment of Genotype 1, 3 and 4 Chronic Hepatitis C Patients with HIV Coinfection, Advanced Cirrhosis and Post-liver Transplant Recurrence of HCV Bristol-Myers Squibb press release / 01 February 2016 Zepatier for hepatitis C approved in Canada CATIE / 01 February 2016 Merck Receives FDA Approval of ZEPATIER™ (elbasvir and grazoprevir) for the Treatment of Chronic Hepatitis C Virus Genotype 1 or 4 Infection in Adults Merck press release / 29 January 2016 The Medicines Patent Pool Signs First Sub-licences for Hepatitis C Medicine Daclatasvir Medicines Patent Pool / 20 January 2016 ← Prev1...34567...45Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Transmission and prevention Diagnosis and monitoring Disease course and symptoms HCV and coinfections Living with HCV Treatment issues Side effects Therapies Liver transplants Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive